Daily Oral Emtricitabine/Tenofovir Preexposure Prophylaxis and Herpes Simplex Virus Type 2 among Men Who Have Sex with Men

BACKGROUND: In addition to protecting against HIV acquisition, antiretroviral preexposure prophylaxis (PrEP) using topical 1% tenofovir gel reduced Herpes simplex virus type 2 (HSV-2) acquisition by 51% among women in the CAPRISA 004 study. We examined the effect of daily oral emtricitabine/tenofovi...

Descripción completa

Detalles Bibliográficos
Autores principales: Marcus, Julia L., Glidden, David V., McMahan, Vanessa, Lama, Javier R., Mayer, Kenneth H., Liu, Albert Y., Montoya-Herrera, Orlando, Casapia, Martin, Hoagland, Brenda, Grant, Robert M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3956614/
https://www.ncbi.nlm.nih.gov/pubmed/24637511
http://dx.doi.org/10.1371/journal.pone.0091513

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3956614/
https://www.ncbi.nlm.nih.gov/pubmed/24637511
http://dx.doi.org/10.1371/journal.pone.0091513

Ejemplares similares